Privia Health Group Inc
$ 22.00
-8.18%
06 Aug - close price
- Market Cap 3,019,256,000 USD
- Current Price $ 22.00
- High / Low $ 22.09 / 19.70
- Stock P/E 140.94
- Book Value 5.99
- EPS 0.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.04 %
- 52 Week High 28.82
- 52 Week Low 19.53
About
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Analyst Target Price
$31.89
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-27 | 2023-11-03 |
| Reported EPS | 0.02 | 0.19 | 0.07 | 0.29 | 0.02 | 0.22 | 0.21 | 0.2 | 0.19 | 0.18 | 0.02 | 0.17 |
| Estimated EPS | 0.08 | 0.25 | 0.04 | 0.22 | 0.05 | 0.18 | 0.2008 | 0.2 | 0.18 | 0.15 | 0.04 | 0.16 |
| Surprise | -0.06 | -0.06 | 0.03 | 0.07 | -0.03 | 0.04 | 0.0092 | 0 | 0.01 | 0.03 | -0.02 | 0.01 |
| Surprise Percentage | -75% | -24% | 75% | 31.8182% | -60% | 22.2222% | 4.5817% | 0% | 5.5556% | 20% | -50% | 6.25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRVA
2026-08-07 06:11:16
Privia Health Group, Inc. (PRVA) published its Q2 2026 earnings call presentation. The company reported an EPS of $0.19, missing estimates by $0.05, but revenue reached $632.63M, beating expectations by $31.87M and representing a 21.39% year-over-year increase. This presentation was released in conjunction with their earnings call.
2026-08-07 01:11:16
Privia Health Group Inc (PRVA) shares fell 8.2% to $22.00, but are considered undervalued by the GF Value™ estimate of $27.63, creating a 20.4% margin of safety. The company has a strong GF Score™ of 88/100, with high ratings for growth and valuation, despite a lower profitability rank and recent insider selling activity totaling $15.0 million. Investors should weigh the undervaluation and strong fundamentals against the insider selling and market volatility.
2026-08-06 16:11:16
Privia Health Group (PRVA) exceeded Q2 2026 earnings expectations, reporting adjusted EPS of $0.19 against a $0.07 estimate, and revenue of $632.6M, a 21.4% increase year-over-year. The company's growth was driven by its expanding provider network and value-based care arrangements, with full-year revenue guidance set at the high end of its forecast. Wall Street analysts maintain a bullish outlook on the stock.
2026-08-06 13:11:16
Privia Health Group, Inc. (NASDAQ: PRVA) reported significant financial growth for Q2 2026, with revenue increasing to $632.6 million and net income rising to $9.0 million. The company also expanded its revolving credit facility to $250 million with no outstanding borrowings, demonstrating strong liquidity. Growth was fueled by an increase in fee-for-service and value-based care, along with strategic acquisitions and an expansion into new geographical markets.
2026-08-06 11:11:16
Privia Health Group, Inc. (NASDAQ:PRVA) reported strong second-quarter results, exceeding analyst expectations with adjusted EPS of $0.19 and revenue of $632.6 million. The company also issued its first fiscal year 2026 revenue guidance, projecting between $2.35 billion and $2.45 billion, with the midpoint slightly below analyst consensus. These results highlight the company's operational execution and continued growth in its technology-driven physician enablement platform.
2026-08-06 08:11:16
Privia Health Group, Inc.'s average stock price target has increased from $31.89 to $32.11, according to estimates from 18 analysts. This updated target implies a 35% potential upside based on the Aug. 4 closing price, with forecasts ranging from $24 to $40 per share. The consensus rating for the stock remains a "Buy" among 19 analysts.
